CareRx Delivers Growth and Successful Refinancing

Carerx Corporation (TSE:CRRX) has released an update.

CareRx Corporation has reported a solid close to 2023 with a third consecutive quarter of growth in Adjusted EBITDA, reaching $7.5 million despite a slight revenue dip to $91.1 million in Q4. The company also managed a net loss reduction compared to the previous year, crediting efficiency measures and cost savings initiatives. Additionally, CareRx successfully refinanced its debt, enhancing its financial position and retiring existing obligations.

For further insights into TSE:CRRX stock, check out TipRanks’ Stock Analysis page.